This article, titled “Pulmonary Hypertension: From Therapeutic Nihilism to Multiple Therapeutic Interventions”, published on November 18, 2024 on Circulation, is undoubtedly encouraging and hopeful, showcasing the tremendous progress made in the field of pulmonary hypertension. It highlights how far we’ve come, from no treatments to over a dozen targeted therapies addressing multiple pathways, improving the quality of life and outcomes for patients. It reflects the power of scientific discovery, collaboration, and innovation in overcoming what was once a seemingly insurmountable condition. While challenges remain, the advancements offer hope for continued breakthroughs that may one day transform pulmonary hypertension from a life-threatening disease to a manageable condition.
Read more at this link on Circulation
SUMMARY
Early Discoveries
- Pulmonary hypertension was first described in 1891 by Dr. Ernst von Romberg.
- In 1929, Dr. Werner Forssmann performed the first heart catheterization (on himself), a technique that earned him and his colleagues a Nobel Prize in 1956.
Advances in Understanding pulmonary hypertension
- In the 1950s, Dr. David Dresdale identified hemodynamic characteristics of pulmonary hypertension and its response to treatments like vasodilators.
- Dr. Paul Wood developed an early classification of pulmonary hypertension and introduced the concept of pulmonary vascular resistance (Wood Units).
Therapeutic Breakthroughs
- Nobel Prize-winning discoveries related to prostaglandins (Sir John Vane) and nitric oxide (Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad) in the 1980s and 1990s enhanced understanding of endothelial dysfunction and informed drug development.
- These discoveries led to multiple therapeutic advances, including the use of prostacyclin itself, approved as continuous intravenous epoprostenol in 1995; the development of other prostacyclin analogs and a prostacyclin receptor agonist; and the development of medications acting on the nitric oxide pathway, including phosphodiesterase type 5 inhibitors and guanylate cyclase stimulators.
- Over the past 30 years, more than a dozen therapies targeting specific pathways (prostacyclin, endothelin, nitric oxide, and activin/transforming growth factor β) have emerged.
- Recent advances include sotatercept, approved in 2024, which improves multiple clinical and functional outcomes.
Expanded Treatment Options
- Therapies have been extended to include conditions like interstitial lung disease–associated pulmonary hypertension and chronic thromboembolic pulmonary hypertension.
- Effective treatments for pulmonary hypertension linked to left heart disease still remain elusive.
Collaborative Efforts
- The American Heart Association and other organizations have led the development of guidelines and risk assessments.
- World Symposia on pulmonary hypertension, held every five years, have shaped modern PH classification and treatment guidelines.
Challenges Ahead
- Despite advancements, pulmonary hypertension remains associated with high mortality.
- Future treatments aim to address underlying cellular dysfunction and reverse vascular remodeling.
- Challenges in clinical trials include the growing prevalence of comorbidities and the need for novel endpoints.
Conclusion
Ongoing international collaboration, timely diagnosis, and optimized therapy use are critical for improving outcomes.
Citation
Pulmonary Hypertension: From Therapeutic Nihilism to Multiple Therapeutic Interventions, Vallerie V. McLaughlin, MD https://orcid.org/0000-0002-8907-1651 vmclaugh@med.umich.edu, and Marc Humbert, MD, PhD, Circulation Volume 150, Number 21 https://doi.org/10.1161/CIRCULATIONAHA.124.070104